TABLE 2.

Results of epicutaneous patch tests conducted prior to (PT1) and during dupilumab treatment (PT2)–stratified by results of PT1

		Patch test during dupilumab (PT2)
		−	+	++	+++	?+	Total
Patch test prior to dupilumab (PT1)	+	25	6	0	0	3	34
	++	12	7	1	0	0	20
	+++	0	0	2	0	0	2
Total		37	13	3	0	3	56

Presentation of results is in accordance with the recommendations of the ICDRG criteria: −, negative reaction; +, weak positive reaction; ++, strong positive reaction; +++, extreme positive reaction; ?+, doubtful reaction.